AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® [Yahoo! Finance]
AIM ImmunoTech Inc. (AIM)
Company Research
Source: Yahoo! Finance
completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at m
Show less
Read more
Impact Snapshot
Event Time:
AIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AIM alerts
High impacting AIM ImmunoTech Inc. news events
Weekly update
A roundup of the hottest topics
AIM
News
- AIM ImmunoTech to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- AIM ImmunoTech to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastGlobeNewswire
AIM
Sec Filings
- 5/15/24 - Form 10-Q
- 5/7/24 - Form 4
- 5/7/24 - Form 4
- AIM's page on the SEC website